blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4115181

EP4115181 - METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  09.12.2022
Database last updated on 18.10.2024
FormerThe international publication has been made
Status updated on  10.09.2021
Formerunknown
Status updated on  16.03.2021
Most recent event   Tooltip10.09.2024New entry: Additional fee for renewal fee: payment of fee 
10.09.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Université de Strasbourg
4, rue Blaise Pascal
67000 Strasbourg / FR
For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
101, rue de Tolbiac
75013 Paris / FR
[2023/02]
Inventor(s)01 / BAUMERT, Thomas
Schwimmbadstrasse 12
79100 Freiburg / DE
02 / LUPBERGER, Joachim
32, rue Médiane
67000 Strasbourg / FR
03 / JÜHLING, Frank Sven
Kahllachweg 5
77694 Kehl / DE
04 / HOSHIDA, Yujin
5120 Briargrove Ln
Dallas, Texas 75287 / US
 [2023/02]
Representative(s)Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[2023/02]
Application number, filing date21710213.602.03.2021
[2023/02]
WO2021EP55203
Priority number, dateUS202062983965P02.03.2020         Original published format: US 202062983965 P
[2023/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021175863
Date:10.09.2021
Language:EN
[2021/36]
Type: A1 Application with search report 
No.:EP4115181
Date:11.01.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 10.09.2021 takes the place of the publication of the European patent application.
[2023/02]
Search report(s)International search report - published on:EP10.09.2021
ClassificationIPC:G01N33/50, G01N33/574
[2023/02]
CPC:
G01N33/57438 (EP); C12Q1/6883 (US); C12N5/067 (US);
C12Q1/6886 (US); G01N33/5067 (EP,US); C12N2506/30 (US);
C12Q2600/118 (US); C12Q2600/136 (US); C12Q2600/158 (US);
G01N2800/085 (EP); G01N2800/52 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/02]
TitleGerman:VERFAHREN ZUR DIAGNOSE UND/ODER PROGNOSE DES FORTSCHREITENS EINER LEBERERKRANKUNG UND DES RISIKOS EINES HEPATOZELLULÄREN KARZINOMS SOWIE ZUR ENTDECKUNG VON THERAPEUTISCHEN VERBINDUNGEN UND ZIELEN ZUR BEHANDLUNG VON LEBERERKRANKUNGEN UND KREBS[2023/02]
English:METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER[2023/02]
French:PROCÉDÉ DE DIAGNOSTIC ET/OU DE PRONOSTIC DE LA PROGRESSION D'UNE MALADIE DU FOIE ET DU RISQUE DE CARCINOME HÉPATOCELLULAIRE ET DÉCOUVERTE DE COMPOSÉS THÉRAPEUTIQUES ET DE CIBLES POUR TRAITER UNE MALADIE DU FOIE ET LE CANCER[2023/02]
Entry into regional phase09.09.2022National basic fee paid 
09.09.2022Designation fee(s) paid 
09.09.2022Examination fee paid 
Examination procedure09.09.2022Examination requested  [2023/02]
09.09.2022Date on which the examining division has become responsible
30.03.2023Amendment by applicant (claims and/or description)
11.05.2023Despatch of communication of loss of particular rights: Claims {1}
Request for further processing for:Loss of rights: Claims
30.05.2023Request for further processing filed
30.05.2023Full payment received (date of receipt of payment)
Request granted
07.06.2023Decision despatched
Fees paidRenewal fee
31.03.2023Renewal fee patent year 03
10.09.2024Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.03.202404   M06   Fee paid on   10.09.2024
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2013009809  (UNIV LELAND STANFORD JUNIOR [US], et al) [Y] 1-13,15-21 * claims 1-15 *;
 [Y]WO2016174130  (UNIV STRASBOURG [FR], et al) [Y] 1-13,15-21 * page 17, line 4 - line 16; claims 1-31 *;
 [X]  - ABDUL M. OSEINI ET AL, "Therapies in non-alcoholic steatohepatitis (NASH)", LIVER INTERNATIONAL, GB, (20170101), vol. 37, doi:10.1111/liv.13302, ISSN 1478-3223, pages 97 - 103, XP055511044 [X] 22 * the whole document *

DOI:   http://dx.doi.org/10.1111/liv.13302
 [ID]  - YUJIN HOSHIDA ET AL, "Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis", GASTROENTEROLOGY, US, (20130501), vol. 144, no. 5, doi:10.1053/j.gastro.2013.01.021, ISSN 0016-5085, pages 1024 - 1030, XP055291337 [ID] 1-13,15-21 * the whole document *

DOI:   http://dx.doi.org/10.1053/j.gastro.2013.01.021
 [I]  - HOSHIDA ET AL, "Supplementary Information: Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis", GASTROENTEROLOGY, US, (20130501), vol. 144, no. 5, doi:10.1053/j.gastro.2013.01.021, ISSN 0016-5085, pages 1 - 39, XP055524997 [I] 1-13,15-21 * the whole document *

DOI:   http://dx.doi.org/10.1053/j.gastro.2013.01.021
 [I]  - MARIA RYABOSHAPKINA ET AL, "Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis", SCIENTIFIC REPORTS, (20170927), vol. 7, no. 1, doi:10.1038/s41598-017-10930-w, page 12361, XP055741376 [I] 1-13,15-21 * the whole document *

DOI:   http://dx.doi.org/10.1038/s41598-017-10930-w
 [I]  - YIM SUN YOUNG ET AL, "Identification of prognostic biomarker in predicting hepatocarcinogenesis from cirrhotic liver using protein and gene signatures", EXPERIMENTAL AND MOLECULAR PATHOLOGY, ACADEMIC PRESS, US, vol. 111, doi:10.1016/J.YEXMP.2019.104319, ISSN 0014-4800, (20191030), (20191030), XP085904773 [I] 1-13,15-21 * abstract *

DOI:   http://dx.doi.org/10.1016/j.yexmp.2019.104319
 [YD]  - KING LINDSAY Y ET AL, "A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration", GUT, BMJ PUBLISHING GROUP, UK, vol. 64, no. 8, doi:10.1136/GUTJNL-2014-307862, ISSN 1468-3288, (20150801), pages 1296 - 1302, (20140820), XP008180832 [YD] 1-13,15-21 * the whole document *

DOI:   http://dx.doi.org/10.1136/gutjnl-2014-307862
by applicantUS4843155
    - BRAY FFERLAY JSOERJOMATARAM I et al., "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin., (20180000), vol. 68, no. 6, pages 394 - 424
    - KANWAL FKRAMER JASCH SM et al., "Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents", Gastroenterology, (20170000), vol. 153, no. 4, doi:10.1053/j.gastro.2017.06.012, pages 996 - 1005 el, XP085196399

DOI:   http://dx.doi.org/10.1053/j.gastro.2017.06.012
    - KIM DLI AAPERUMPAIL BJ et al., "Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States", Hepatology, (20190000), vol. 69, no. 3, pages 1064 - 74
    - FUJIWARA NFRIEDMAN SLGOOSSENS N et al., "Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine", J Hepatol., (20170000), vol. 68, no. 3, pages 526 - 549
    - POLAK PKARLIC RKOREN A et al., "Cell-of-origin chromatin organization shapes the mutational landscape of cancer", Nature, (20150000), vol. 518, no. 7539, pages 360 - 364
    - HAMDANE NJUHLING FCROUCHET E et al., "HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response", Gastroenterology, (20190000), vol. 156, no. 8, pages 2313 - 2329
    - PEREZ SKASPI ADOMOVITZ T et al., "Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals", PLoS Genet, (20190000), vol. 15, no. 6, page el008181
    - BERDASCO MESTELLER M, "Clinical epigenetics: Seizing opportunities for translation", Nature Reviews Genetics, (20190000), vol. 20, no. 2, doi:10.1038/s41576-018-0074-2, pages 109 - 27, XP036675876

DOI:   http://dx.doi.org/10.1038/s41576-018-0074-2
    - HARDY TMANN DA, "Epigenetics in liver disease: From biology to therapeutics", Gut., (20160000), vol. 65, no. 11, pages 1895 - 1905
    - PEREZ-SALVIA MESTELLER M, "Bromodomain inhibitors and cancer therapy: From structures to applications", Epigenetics, (20160000), vol. 12, no. 5, doi:10.1080/15592294.2016.1265710, pages 323 - 39, XP055452716

DOI:   http://dx.doi.org/10.1080/15592294.2016.1265710
    - SCHMIDL CRENDEIRO AFSHEFFIELD NC et al., "ChlPmentation: fast, robust, low-input ChlP-seq for histones and transcription factors", Nature Methods, (20150000), vol. 12, no. 10, pages 963 - 5
    - BOLDANOVA TSUSLOV AHEIM MH et al., "Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver", EMBO Molecular Medicine, (20170000), vol. 9, no. 6, pages 816 - 834
    - FEBBRAIO MAREIBE SSHALAPOUR S et al., "Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?", Cell Metab, (20190000), vol. 29, no. 1, doi:10.1016/j.cmet.2018.10.012, pages 18 - 26, XP085576382

DOI:   http://dx.doi.org/10.1016/j.cmet.2018.10.012
    - LUPBERGER JCROONENBORGHS TROCA SUAREZ AA et al., "Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development", Gastroenterology, (20190000), vol. 157, no. 2, doi:10.1053/j.gastro.2019.04.003, pages 537 - 551, XP085741773

DOI:   http://dx.doi.org/10.1053/j.gastro.2019.04.003
    - KING LYCANASTO-CHIBUQUE CJOHNSON KB et al., "A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration", Gut, (20150000), vol. 64, no. 8, doi:10.1136/gutjnl-2014-307862, pages 1296 - 302, XP008180832

DOI:   http://dx.doi.org/10.1136/gutjnl-2014-307862
    - HOSHIDA Y, "Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment", PloS One, (20100000), vol. 5, no. ll, page el5543
    - REICH MLIEFELD TGOULD J et al., Genepattern 2.0. Nature Genetics, (20060000), vol. 38, no. 5, pages 500 - l
    - SUBRAMANIAN ATAMAYO PMOOTHA VK et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles", Proc Natl Acad Sci., (20050000), vol. 102, no. 43, doi:10.1073/pnas.0506580102, pages 15545 - 50, XP002464143

DOI:   http://dx.doi.org/10.1073/pnas.0506580102
    - NAKAGAWA SWEI LSONG WM et al., "Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition", Cancer Cell., (20160000), vol. 30, no. 6, doi:10.1016/j.ccell.2016.11.004, pages 879 - 90, XP029845237

DOI:   http://dx.doi.org/10.1016/j.ccell.2016.11.004
    - JUNG HRKANG HMRYU JW et al., "Cell Spheroids with Enhanced Aggressiveness to Mimic Human Liver Cancer In Vitro and In Vivo", Sci Rep., (20170000), vol. 7, no. 1, page 10499
    - SONG YKIM JSKIM SH et al., "Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma", J Exp Clin Cancer Res., (20180000), vol. 37, no. 1, page 109
    - SANDHU DSBAICHOO EROBERTS LR, "Fibroblast growth factor signaling in liver carcinogenesis", Hepatology, (20140000), vol. 59, no. 3, pages 1166 - 73
    - RUAN WPAN RSHEN X et al., "cDHll promotes liver fibrosis via activation of hepatic stellate cells", Biochem Biophys Res Commun, (20190000), vol. 508, no. 2, pages 543 - 9
    - LU JXIA YCHEN K et al., "Oncogenic role of the Notch pathway in primary liver cancer", Oncology Letters, (20160000), vol. 12, no. 1, pages 3 - 10
    - TEE ARFINGAR DCMANNING BD et al., "Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling", Proc Natl Acad Sci USA., (20020000), vol. 99, no. 21, pages 13571 - 6
    - HOSHIDA YVILLANUEVA ASANGIOVANNI A et al., "Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis", Gastroenterology, (20130000), vol. 144, no. 5, doi:10.1053/j.gastro.2013.01.021, pages 1024 - 30, XP055291337

DOI:   http://dx.doi.org/10.1053/j.gastro.2013.01.021
    - KANWAL FKRAMER JRMAPAKSHI S et al., "Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease", Gastroenterology, (20180000), vol. 155, no. 6, doi:10.1053/j.gastro.2018.08.024, pages 1828 - 37 e2, XP085546382

DOI:   http://dx.doi.org/10.1053/j.gastro.2018.08.024
    - BAUHOFER ORUGGIERI ASCHMID B et al., "Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response", Gastroenterology, (20120000), vol. 143, no. 2, doi:10.1053/j.gastro.2012.04.018, pages 429 - 38, XP028449326

DOI:   http://dx.doi.org/10.1053/j.gastro.2012.04.018
    - CHRISTEN VTREVES SDUONG FHT et al., "Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A", Hepatology, (20070000), vol. 46, no. 2, pages 558 - 65
    - EGNATCHIK RALEAMY AKJACOBSON DA et al., "ER calcium release promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate overload", Molecular metabolism, (20140000), vol. 3, no. 5, pages 544 - 53
    - SEHGAL PSZALAI POLESEN C et al., "Inhibition of the sarco/endoplasmic reticulum (ER) Ca2+-ATPase by thapsigargin analogs induces cell death via ER Ca2+ depletion and the unfolded protein response", The Journal of Biological Chemistry, (20170000), vol. 292, no. 48, doi:10.1074/jbc.M117.796920, pages 19656 - 73, XP055690041

DOI:   http://dx.doi.org/10.1074/jbc.M117.796920
    - BOWERS EMYAN GMUKHERJEE C et al., "Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor", Chem Biol., (20100000), vol. 17, no. 5, doi:10.1016/j.chembiol.2010.03.006, pages 471 - 82, XP055575681

DOI:   http://dx.doi.org/10.1016/j.chembiol.2010.03.006
    - CALO EWYSOCKA J, "Modification of enhancer chromatin: what, how, and why?", Mol Cell, (20130000), vol. 49, no. 5, doi:10.1016/j.molcel.2013.01.038, pages 825 - 37, XP028590128

DOI:   http://dx.doi.org/10.1016/j.molcel.2013.01.038
    - KARATAS HTOWNSEND ECCAO F et al., "High-affinity, small-molecule peptidomimetic inhibitors of MLLl/WDR5 protein-protein interaction", J Am Chem Soc., (20130000), vol. 135, no. 2, pages 669 - 82
    - LOBERA MMADAUSS KPPOHLHAUS DT et al., "Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group", Nature chemical biology, (20130000), vol. 9, no. 5, pages 319 - 25
    - VIGUSHIN DMALI SPACE PE et al., "Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo", Clin Cancer Res., (20010000), vol. 7, no. 4, pages 971 - 6
    - BAYO JFIORE EJDOMINGUEZ LM et al., "A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets", J Hepatol., (20190000), vol. 71, no. 1, doi:10.1016/j.jhep.2019.03.007, pages 78 - 90, XP085718914

DOI:   http://dx.doi.org/10.1016/j.jhep.2019.03.007
    - DELMORE JEISSA GCLEMIEUX ME et al., "BET bromodomain inhibition as a therapeutic strategy to target c-Myc", Cell, (20110000), vol. 146, no. 6, doi:10.1016/j.cell.2011.08.017, pages 904 - 17, XP028295705

DOI:   http://dx.doi.org/10.1016/j.cell.2011.08.017
    - HONG SHEUN JWCHOI SK et al., "Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer", Oncotarget, (20160000), vol. 7, no. 22, pages 32628 - 40
    - LI GQGUO WZZHANG Y et al., "Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression", Oncotarget, (20160000), vol. 7, no. 3, doi:10.18632/oncotarget.6275, pages 2462 - 74, XP055767400

DOI:   http://dx.doi.org/10.18632/oncotarget.6275
    - LEE JSCHU ISMIKAELYAN A et al., "Application of comparative functional genomics to identify best-fit mouse models to study human cancer", Nature Genetics, (20040000), vol. 36, no. 12, pages 1306 - 11
    - ZANCONATO FBATTILANA GFORCATO M et al., "Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4", Nature Medicine, (20180000), vol. 24, no. 10, doi:10.1038/s41591-018-0158-8, pages 1599 - 610, XP036608988

DOI:   http://dx.doi.org/10.1038/s41591-018-0158-8
    - NICOLAS GFRANCESCO N, "Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection", Reviews on Recent Clinical Trials, (20140000), vol. 9, no. 3, pages 204 - 9
    - FUJIMOTO AFURUTA MTOTOKI Y et al., "Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer", Nature Genetics, (20160000), vol. 48, pages 500 - 9
    - SCHULZE KIMBEAUD SLETOUZE E et al., "Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets", Nature Genetics, (20150000), vol. 47, no. 5, doi:10.1038/ng.3252, pages 505 - 11, XP055392299

DOI:   http://dx.doi.org/10.1038/ng.3252
    - FORNER AREIG MBRUIX J, "Hepatocellular carcinoma", The Lancet, (20180000), vol. 391, no. 10127, pages 1301 - 14
    - VILLANUEVA A, "Hepatocellular carcinoma", N Engl J Med., (20190000), vol. 380, no. 15, pages 1450 - 62
    - DING NHAH NYU RT et al., "BRD4 is a novel therapeutic target for liver fibrosis", Proc Natl Acad Sci USA., (20150000), vol. 112, no. 51, pages 15713 - 8
    - STRATTON MSHALDAR SMMCKINSEY TA, "BRD4 inhibition for the treatment of pathological organ fibrosis", FlOOOResearch, (20170000), vol. 6, page F1000
    - STATHIS ABERTONI F, "BET Proteins as Targets for Anticancer Treatment", Cancer Discovery, (20180000), vol. 8, no. l, pages 24 - 36
    - KLEINER DEBRUNT EMVAN NATTA M et al., "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, (20050000), vol. 41, doi:10.1002/hep.20701, pages 1313 - 21, XP055123202

DOI:   http://dx.doi.org/10.1002/hep.20701
    - "Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group", Hepatology, (19940000), vol. 20, pages 15 - 20
    - BEDOSSA PPOYNARD T, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group", Hepatology, (19960000), vol. 24, pages 289 - 93
    - VERRIER ERCOLPITTS CCBACH C et al., "A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses", Hepatology, (20160000), vol. 63, pages 35 - 48
    - YAN HZHONG GXU G et al., "Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus", Elife, (20120000), vol. l, page e00049
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.